Determination of Cyanuric Acid by Electrochemical Cyclic Voltammetry Method Using CuGeO3 Nanowires as Modified Electrode Materials

A simple electrochemical method for the determination of cyanuric acid (CA) has been developed based on a CuGeO3 nanowire modified glassy carbon electrode. The dense CuGeO3 nanowire film can be formed on the surface of the glassy carbon electrode. The roles of scan rate, CA concentration, and electrolytes with different pH values on the electrochemical responses of CA have also been analyzed. The intensities of two anodic peaks vary linearly with the increase of the scan rate from 25 to 200 mVs−1. The intensity of the electrochemical CV peak increases with the increase of the acidity of the electrolytes. The two anodic peak currents are linear with the CA concentration in the range of 0.005–2 mM. The linear correlation coefficient is 0.984 and 0.980 for the cyclic voltammogram peaks (cvp) cvp1 and cvp2, respectively. The detection limit is 4.3 μM and 2.1 μM for cvp1 and cvp2, respectively. The proposed electrochemical method is convenient and effective sensing of CA.

Trial of antiepilepsirine (AES) in children with epilepsy

Antieplepsirine (AES) is a new antiepileptic drug (AED) which was originally extracted from a Chinese folk remedy, and is now chemically characterized and synthesized. Its chemical structure is different from those of other available AEDs. Animal experiments involving AES demonstrated significant antiepileptic activity. Only a few clinical studies of AES with open trial have been resorted, none of which were on children. A 6.5 month, add-on, double-blind, placebo-controlled, randomized, cross-over study on AES (10 mg/kg per day) was conducted on epileptic children (aged 1-14 years) refractory to treatment with standard AEDs. The seizure frequency was recorded, and the blood levels of AES and other co-medicated AEDs (phenobarbital, phenytoin, carbamazepine and valproate) were determined. Although not planned, patients or parents were allowed to refuse to cross-over to the alternate therapy. The results were compared to the children who crossed-over as well as for the entire group during the first 3 months of randomized treatment. A total of 58 children entered, but only 34/58 children completed the cross-over study. The 24 children whose parents refused to let them be crossed-over continued the original study treatment (AES or placebo) for the entire 6 months. There was no statistically significant difference in seizure control when the entire group of 58 patients was compared to a parallel study group for the first 3 months of therapy (P = 0.178). There was a significant difference (P<0.01) in seizure control between AES and placebo treatment for the 34 patients who completed the entire cross-over study. No significant changes were seen in the blood level of other AEDs, and no serious acute side effects were observed. The results of the present study indicate the efficacy of AES for epileptic children with refractory seizures.

[Seizure activity and lesions of neuronal cells by intrahippocampal injection of guanidinosuccinic acid in rats]

Intrahippocampal injection(ihci) of guanidinosuccinic acid (GSA) to rats, induced typical generarized clonic seizures and epileptiform discharges in electrohippocampogram (EHG) and electrocorticogram (ECoG), degenerative changes of neuronal cells in the injected side hippocampus. The pyramidal cells in CA1 area were found to be more vulnerable to GSA than the granular cells. Phenobarbital and phenytoin are typical antiepiletics, but in no case did they successfully protect against GSA induced convulsions, epileptiform discharges in the EHG and ECoG and neurolysis. Ketamine, a selective noncompetitive NMDA receptor antagonist, was shown to protect against not only seizures, but also neuronal cell damage induced by GSA. All these results indicate that GSA very like the endogenous excitatory amino acid, glutamic acid, it also has such effects mentioned above. Therefore, the NMDA receptor may mediate both effects of GSA.

Anticonvulsant activity of piperine on seizures induced by excitatory amino acid receptor agonists

In traditional Chinese medicine, a mixture of radish and pepper is used to treat epilepsy. The presumptive effectiveness of this prescription might be due to the anticonvulsant actions of the principal component of pepper, the alkaloid piperine (CAS 94-62-2). The effects of piperine on convulsions induced in mice by agonists at different excitatory amino acid receptor subtypes were studied. Piperine was shown to significantly block convulsions induced by intracerebroventricular injection of threshold doses of kainate, but to have no or only slight effects on convulsions induced by L-glutamate, N-methyl-D-aspartate or guanidinosuccinate. Piperine suspensions, injected intraperitoneally, 1 h before injection of the threshold intracerebroventricular dose of kainate for the induction of clonic convulsions (1 nmol), blocked these convulsions with an ED50 (and 95% confidence interval) of 46 (25-86) mg/kg. Although piperine did block convulsions, induced by kainate, the compound does not appear to act as a kainate receptor antagonist. Whole-cell currents induced by the application of kainate to spinal cord cells in primary dissociated cultures were not affected by co-application of piperine.

Epileptiform activity and hippocampal damage produced by intrahippocampal injection of guanidinosuccinic acid in rat

Guanidinosuccinic acid (GSA) is a guanidino compound found in mammalian central nervous system and physiological fluids. Its level has been found to be greatly increased in serum and cerebrospinal fluid of patients with renal failure, and the compound is suggested to play a role in uremic encephalopathy. In this report we examined the behavioral, electrographic and morphological effects of intrahippocampal GSA injection in unanesthetized rats. Intrahippocampal administration of 2 microliters GSA solution (3.5 nM) was followed by behavior observation, and electrohippocampographic and electrocorticographic recording. GSA-injected animals showed partial clonic seizures leading to generalized clonic seizures, and eventually status epilepticus. These were accompanied by epileptiform electrographic discharges. During generalized clonic seizures, the electrohippocampogram showed arythmic bursting spikes. Epileptiform electric activity persisted even after the generalized clonic convulsions had stopped, and lasted until the animals were killed, 5 days following injection. Microscopic examination of brain slices of these rats revealed severe neural damage in CA1 area of hippocampus. Treatment of rats with the non-competitive NMDA receptor antagonist ketamine prevented both partial and generalized clonic seizures, epileptiform electrographic discharges, and GSA-induced hippocampal damage.

Ontogenetic differences in convulsive action and cerebral uptake of uremic guanidino compounds in juvenile mice

Guanidinosuccinate (GSA) and methylguanidine (MG) are endogenous, convulsant guanidino compounds which have been shown to be greatly increased in uremic patients. In the present study, we have investigated the age-related differences in convulsive action and cerebral uptake of these compounds in juvenile mice of 7, 14 and 21 days old. An age-dependent decrease was apparent in the severity of the GSA- and MG-induced convulsions and toxicity. Mean latency for the appearance of clonic convulsions increased with increasing age. Two hours following the i.p. injection of GSA or MG in a dose of 250 mg/kg, the resulting brain concentration decreased with increasing age of the animals. This effect was more pronounced in the case of MG. Neither for GSA, nor for MG was this age-dependent effect apparent after 30 min. GSA and MG serum as well as brain concentrations were lower in 21-day-old mice than in 7-day-old ones. However, the brain/serum concentration ratios of GSA and of MG were significantly lower in 21-day-old mice than in 7-day-old ones, indicating that at least part of the difference in brain level can be explained by higher permeability of the immature blood-brain barrier to these uremic guanidino compounds. In addition, brain/serum ratios of GSA in mice of 7 days old and in mice of 21 days old were significantly lower than the ratios of MG in these age groups, indicative of lower overall blood-brain barrier permeability to GSA than to MG.(ABSTRACT TRUNCATED AT 250 WORDS)

N-methyl-D-aspartate receptors contribute to guanidinosuccinate-induced convulsions in mice

Increased levels of the endogenous convulsant guanidinosuccinate (GSA) might contribute to the epileptic symptomatology presenting in patients with renal failure. Little is known, however, about the underlying epileptogenic mechanism of guanidinosuccinate-induced convulsions. In this paper, we present pharmacological evidence for a direct excitatory action of this compound. In particular, the close involvement of N-methyl-D-aspartate (NMDA) receptors in the pathogenesis of GSA-induced generalized convulsions is suggested. GSA potentiated NMDA-induced convulsions significantly, but not L-glutamate- or kainate-induced convulsions. Conversely, and in addition, NMDA receptor antagonists, like D(-)-2-amino-5-phosphonovalerate, CGP 37849 [DL)-(E)-2-amino-4-methyl-5-phosphono-3-pentenoate] or ketamine (but not kynurenate), blocked the convulsions induced by i.c.v. injection of GSA dose dependently whereas anti-epileptic drugs, like carbamazepine, diazepam, phenobarbital or valproate, only abolished the tonic extension phase of these convulsions. Thus, NMDA receptors appear to be involved, at least partly, in GSA-induced convulsions.

The uremic guanidino compound guanidinosuccinic acid induces behavioral convulsions and concomitant epileptiform electrocorticographic discharges in mice

As yet, the in vivo epileptogenic properties of guanidinosuccinic acid (GSA) remained highly conjectural, still requiring the demonstration of GSA-induced behavioral convulsions accompanied by epileptiform electrographic discharges. Therefore, Swiss mice were injected intraperitoneally (i.p.) with increasing doses of GSA. Full-blown clonic or clonic-tonic convulsions appeared in a dose-dependent manner, with a median latency of about 25 min. CD50 (convulsive dose of the drug in 50% of the animals), the LD50 (lethal dose in 50%), and their 95% confidence limits for GSA suspensions in i.p. administration were 363 (287-458) mg/kg and 579 (445-756) mg/kg, respectively. In addition, four-channel electrocorticographic (ECoG) recordings were made in freely moving mice following the injection of 700 mg/kg (CD97). Epileptiform ECoG discharges coincided with the behavioral manifestation of the GSA-induced convulsions starting with initial decrease in amplitude, occasional spike-waves (10-20 min after injection), eventually leading to sustained spiking and spike-wave activity (30-50 min after injection). Clonic convulsions induced by a CD97 dose of GSA were only moderately attenuated by high doses of i.p. phenobarbital (20, 40 and 80 mg/kg), while tonic extension and lethal effects were dose-dependently blocked. A dose of 1000 mg/kg (CD97 for tonic extension) induced tonic extension in 100% of the animals, following treatment with 20 mg/kg of phenytoin none of the animals displayed tonic extension, and following 10 mg/kg only 30% of the animals displayed tonic extension, while the occurrence of clonic convulsions was not significantly attenuated.

Behavioral toxicity of guanidinosuccinic acid in adult and young mice

Guanidinosuccinic acid (GSA), a guanidino compound found to be greatly increased in uremia, was administered by intraperitoneal (i.p.) injection to adult albino mice and to young mice 7, 14 and 21 days old. Epileptogenic and toxic properties were assessed and GSA brain levels following i.p. injection were determined. In adult mice, GSA induced long-lasting generalized clonic and clonic-tonic convulsions in a dose-dependent manner with a CD50 (and 95% confidence interval) of 363 (287-458) mg/kg (n = 35), and an LD50 of 579 (445-756) mg/kg. The CD50 of GSA corresponded with a brain concentration of 56 nmol/g tissue. Electrocorticographic recording in five adult mice revealed epileptiform discharges (spikes, spike-waves, and polyspike-waves) which appeared concomitant with the convulsions. When young mice were i.p. injected with a (for adults) subconvulsive dose of GSA (250 mg/kg), an age-dependent decrease was noted in GSA-induced convulsions and in the resulting brain concentration. The presented findings suggest that GSA could be an important uremic toxin which could contribute to the epileptic symptomatology in uremia.

Convulsive action and toxicity of uremic guanidino compounds: behavioral assessment and relation to brain concentration in adult mice

Four guanidino compounds that are known to accumulate in uremia, namely creatinine, guanidine, guanidinosuccinic acid and methylguanidine, were administered intraperitoneally and intracerebroventricularly to adult albino mice and the compounds epileptogenic and toxic properties were behaviorally assessed. After intraperitoneal injection, brain concentration of the compounds as a function of injected dose was monitored additionally. Guanidino compound brain concentration was determined by cation exchange chromatography with fluorescence ninhydrin detection. After systemic administration, especially guanidinosuccinic acid and methylguanidine induced long-lasting generalized convulsions which gradually increased in severity. Increasing the dose injected intraperitoneally resulted in linear increase in brain concentration of the injected compounds, in parallel with increase in proportion of animals presenting with convulsions and/or severity of convulsions. Guanidinosuccinic acid brain concentration increased more slowly than that of the other 3 compounds and guanidinosuccinic acid also exerted its effect later than the others. Since none of the other metabolically related guanidino compounds determined was significantly increased in the brains of the injected animals, the observed behavior was most certainly induced by the compounds injected and not by some secondary metabolite. Epileptogenic properties of the four compounds were markedly and qualitatively different in systemic administration, but rather similar in intracerebral administration. A tentative epileptogenic potency order was inferred from the combined behavioral and biochemical results. All 4 of the compounds tested displayed the ability to induce full-blown clonic-tonic convulsions and they did so in a dose-related manner. Guanidinosuccinic acid appeared to be slightly more potent than methylguanidine, but both guanidinosuccinic acid and methylguanidine were considerably more potent than guanidine. Creatinine was many times less potent than the other 3 guanidino compounds. Revised epileptogenic potency order on the basis of guanidino compound brain concentration after systemic administration as well as potency order after intracerebral administration paralleled the potency order of these compounds in their GABA antagonism reported earlier. It was therefore postulated that the GABA antagonism of uremic guanidino compounds could underlie their epileptogenic character. Moreover, these compounds could very likely be at the basis of the neurological complications including epilepsy of uremic patients in whom they accumulate in physiological fluids and brain.

Chemical models of epilepsy with some reference to their applicability in the development of anticonvulsants

This paper reviews chemical models of epilepsy and their relevance in the identification and characterization of anticonvulsants. For each convulsant we discuss possible modes of administration, clinical type(s) of seizures induced, proposed mechanism(s) of epileptogenesis and, where available, responsiveness of the induced seizures to anticonvulsants. The following compounds are reviewed: pentylenetetrazol, bicuculline, penicillin, picrotoxin, beta-carbolines, 3-mercaptopropionic acid, hydrazides, allylglycine; the glycine antagonist strychnine; gamma-hydroxybutyrate; excitatory amino acids (glutamate, aspartate, N-methyl-D-aspartate, quisqualate, kainate, quinolinic acid); monosubstituted guanidino compounds, metals (alumina, cobalt, zinc, iron); neuropeptides (opioid peptides, corticotropin releasing factor, somatostatin, vasopressin); cholinergic agents (acetylcholine, acetylcholinesterase inhibitors, pilocarpine); tetanus toxin; flurothyl; folates; homocysteine and colchicine. Although there are a multitude of chemical models of epilepsy, only a limited number are applied in the routine screening of potential anticonvulsants. Some chemical models have a predictive value with regard to the clinical profile of efficacy of the tested anticonvulsants. Some chemical models may contribute to a better understanding of possible mechanisms of epileptogenesis.

Double-blind crossover controlled study on antiepilepsirine

Antiepilepsirine (AES) is one of the derivatives of a Chinese folk prescription. It is a new antiepileptic drug (AED) synthesized in cooperation by Chinese medical and pharmaceutical workers. Pharmacological experiments on animal models prove that its antiepileptic action is marked, but there has been little evaluation of its clinical effects. We used the double-blind placebo-controlled crossover study which is generally acceptable as a proper method for new drug study. This study covered 58 epileptic children treated with classical AEDs and observed 6.5 months. Every patient took AES and placebo for 3 months each by random crossover on the basis of add-on therapy. The blood levels of AES and other antiepileptic drugs were determined regularly. The results show that there are no significant differences in clinical effects between AES and placebo in pediatric epilepsies as a whole, but AES is effective in tonic-clonic seizures (P less than 0.05), the most common type of seizure in the series. There are no significant differences in AED blood levels between the AES effective and ineffective groups. AES has no effect on the blood levels of other AEDs. AES is very safe, children given large doses (10 mg/kg/day) demonstrate no serious side-effects. It is suggested that there is potential improvement in patient psychological and cognitive status. This article also discusses the evaluation of new drugs for clinical effects, subject sampling, the criteria for efficacy evaluation and relationship between animal information and human outcome. The AES chemical structure is different from other well-known AEDs, this is a unique advantage.(ABSTRACT TRUNCATED AT 250 WORDS)

Features of seizures and behavioral changes induced by intrahippocampal injection of zinc sulfate in the rabbit: a new experimental model of epilepsy

Seizure produced by intrahippocampal injection of zinc sulfate in rabbits is a new chronic model of experimental epilepsy. In this model, the clinical manifestations are easily observed and are expressed not only as partial clonic seizures, but also by secondary generalized seizures. The electrohippocampalogram (EHG) and electrocorticogram (ECoG) discharges change correspondingly during both types of seizures, and last for weeks. The mechanism for induced seizures may be partly related to the inhibitory effect of zinc sulfate injections on the acetylcholinesterase (AchE) activity in the hippocampus. The commonly used antiepileptic drugs, such as phenobarbital and phenytoin, afforded protection against the zinc-induced secondary generalized clonic seizures and alleviated the partial clonic seizures but had no influence on the EHG- and ECoG-monitored periodic bursts of spike discharges. Nitrazepam was found to antagonize both types of seizures and also transiently restored the EHG and ECoG to normal. D-penicillamine, a metal chelator, may be the most effective agent for the treatment of zinc-induced seizures; the agent, in addition to affording protection against both types of seizures, also caused the periodic burst spike discharges in EHG and ECoG to disappear.

Kindling phenomenon of hyperthermic seizures in the epilepsy-prone versus the epilepsy-resistant rat

A kindling-like effect was produced by exposing 30-day-old rats to repeated hyperthermia-induced seizures. Naive audiogenic seizure (AGS)-susceptible rats (P77PMC) were easier to be kindled than AGS-resistant rats (Wistar). This hyperthermic kindling model may be used to study the outcome and mechanisms of human febrile seizures. The mechanisms underlying hyperthermic kindling remain to be investigated.

Effects of piperine on convulsions and on brain serotonin and catecholamine levels in E1 mice

Convulsions of E1 mice were completely suppressed by 60 mg/kg of piperine injected intraperitoneally. The ED50 was 21.1 mg/kg. The brain 5-HT, dopamine and norepinephrine levels were estimated 1 hour after the intraperitoneal injection of piperine. The 5-HT level was significantly higher in the cerebral cortex of piperine treated mice than in control mice. This increase may be related directly to the mechanism of inhibition of convulsions by piperine. On the other hand, lower levels of 5-HT were observed in the hippocampus, midbrain and cerebellum. The dopamine level in the piperine treated mice was markedly higher only in the hypothalamus, while the norepinephrine levels were lower in every part of the brain.

Long-term effects of febrile convulsion on seizure susceptibility in P77PMC rat--resistant to acoustic stimuli but susceptible to kainate-induced seizures

A new audiogenic seizure (AGS)-susceptible strain of rats (P77PMC) was evaluated as a possible model of human febrile seizures. The long-term effects of experimental febrile seizures were observed. All 30-day-old rat pups exhibited clonic seizures during exposure to an ambient temperature of 45 +/- 0.5 degree C. The mean latency from the beginning of the hyperthermic stimulus to the onset of convulsion was 16.9 +/- 2.2 min. The rats survived this hyperthermic seizure, developed a resistance to acoustic stimulations, but were more susceptible at the age of 50 to 60 days to kainate-induced limbic seizures than controls. The results of this study imply that febrile seizures of developing P77PMC rats can change later seizure susceptibility, and there may be some correlation between febrile convulsion and temporal lobe epilepsy.

A review of pharmacology and clinical use of piperine and its derivatives

Piperine and its derivatives are effective anticonvulsant drugs that antagonize convulsions induced by physical and chemical methods. Their major anticonvulsant activity as shown in animal tests lies in modification of the maximal electroshock seizure pattern. They also have sedative-hypnotic, tranquilizing, and muscle-relaxing actions and can intensify the depressive action of other depressants, when used in combination. Antiepilepsirine, one of the derivatives of piperine, is used as an antiepileptic drug in treating different types of epilepsy. It has been proved effective and is being widely used in China. The anticonvulsant action of 7446, 7448, and 7903 is more potent than that of antiepilepsirine. The chemical structure of piperine and its derivatives is different from that of prototype antiepileptic drugs, and, therefore, these may become a new group of antiepileptic drugs.